Insights

Even with strong protocols and qualified investigators, many clinical trials experience delays that have nothing to do with science. Instead, they originate from administrative weaknesses that quietly slow progress, inflate costs, and strain research staff. Let’s look at the administrative weaknesses that most often impede the efficiency of trials, along with practical solutions that can be put in place by organizations to enhance their performance and protect study timelines.

Patient safety, credible data, and the investigator’s responsibilities are equally important, but the investigator’s responsibilities are the most actionable, and help drive patient safety and credible data. They are also best facilitated by strong, professional relationships between investigators and other members of the clinical trials team.